Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Robert A. Scott, M.D., appointed Chief Medical Officer of Cerenis Therapeutics


Toulouse, France & Ann Arbor, Michigan, January 23, 2008 - Cerenis Therapeutics SA, a privately held pharmaceutical company developing HDL compounds for the treatment of cardiovascular and metabolic diseases, today announced the appointment of Rob Scott, M.D., as the company's chief medical officer. Dr. Scott brings to the company more than 20 years of experience leading global cardiovascular drug development programs through clinical development to highly successful commercialization.

Most recently Dr. Scott served as executive vice president of research and development at AtheroGenics, Inc., a pharmaceutical company focused on the treatment of chronic inflammatory diseases. At AtheroGenics Dr. Scott oversaw development efforts in the areas of atherosclerosis, diabetes, rheumatoid arthritis and asthma. Previously, Dr. Scott was worldwide therapeutic head of the cardiovascular and metabolic group at Pfizer. In that role Dr. Scott was responsible for the development teams that produced: NORVASC®, the most-prescribed drug for high blood pressure; LIPITOR®, the most prescribed drug for high LDL cholesterol and the world's best-selling drug; CADUET®, the first combination drug for the simultaneous management of two separate disease states; and other products for the treatment of diabetes and cardiac arrhythmias.

“We are honored to have Dr. Scott on board as our CMO. His deep expertise in developing novel cardiovascular treatments and his highly impressive track record in guiding blockbuster therapies through clinical development will make him a great asset to our company. For Cerenis, the appointment of Dr. Scott is a crucial step as we advance from a preclinical to a clinical development focus,” said Jean-Louis Dasseux, Ph.D., President and CEO of Cerenis.

-ENDS-

About Cerenis Therapeutics
Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases. Based on pioneering research conducted by the Cerenis team of world leaders in HDL therapy, the company is pursuing a range of HDL product candidates that are positioned to represent major advances in patient care and significant commercial opportunities in the treatment of cardiovascular and metabolic diseases. Cerenis has operations in Ann Arbor, Michigan and Toulouse, France. For further information please visit www.cerenis.com.

For further information, please visit www.cerenis.com.

- ends –


Further enquiries:

Europe:

College Hill
Tel: +44 (0)20 7866 7856

Holly Griffiths, Senior Account Executive
holly.griffiths@collegehill.com

Tony Stephenson, Senior Account Manager
tony.stephenson@collegehill.com

USA:

Berry & Company Public Relations
Tel: (212) 253-8881


Publisher Contact Information:

College Hill
+44 (0)20 7866 7856
holly.griffiths@collegehill.com

Company profile of Cerenis Therapeutics SA
Past press releases of Cerenis Therapeutics SA.

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.